Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Rhythm Pharmaceuticals / Equity Bottom-Up

<ul><li>Rhythm Pharmaceuticals recently conducted their Q2 2025 earnings conference call, providing insights into their financial performance and operational progress.</li><li>The company reported a strong quarter, marked by significant financial achievements and promising developments in their clinical pipeline.</li><li>Financially, Rhythm Pharmaceuticals presented robust global revenue of $48.5 million for Q2, representing a 29% increase from the previous quarter.</li></ul>

Rhythm Pharmaceuticals recently conducted their Q2 2025 earnings conference call, providing insights into their financial performance and operational progress.The company reported a strong quarter, marked by significant financial achievements and promising developments in their clinical pipeline.Financially, Rhythm Pharmaceuticals presented robust global revenue of $48.5 million for Q2, representing a 29% increase from the previous quarter.

Rhythm Pharmaceuticals: A Growing Pipeline With Next-Gen MC4R Agonists – Could Bivamelagon Be the Game-Changer?

United States

Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company specializes in the development of molecule therapies targeting metabolic pathways for the treatment of obesity, diabetes, and gastrointestinal functional disorders. Rhythm Pharmaceuticals serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rhythm Pharmaceuticals (RYTM US)

Rhythm Pharmaceuticals: A Growing Pipeline With Next-Gen MC4R Agonists – Could Bivamelagon Be the Game-Changer?

Rhythm Pharmaceuticals recently conducted their Q2 2025 earnings conference call, providing insights into their financial performance and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)